Cayuga Biotech is a clinical-stage company developing novel therapeutics to address hemorrhage by harnessing the body’s innate ability to stop bleeding. Cayuga’s pipeline includes CAY001 (polyP-SNP complex), in development for life-threatening hemorrhage; CAY002, a discovery-stage program for inherited bleeding disorders; and a portfolio of additional early-stage programs across the healing continuum.